AAVANTGARDE BIO
AAVantgarde Bio is developing gene therapies for inherited retinal disorders.
AAVANTGARDE BIO
Industry:
Biotechnology Health Care Therapeutics
Founded:
2021-01-01
Address:
Milano, Lombardia, Italy
Country:
Italy
Website Url:
http://www.aavantgardebio.com
Status:
Active
Email Addresses:
[email protected]
Total Funding:
0
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Font API LetsEncrypt Apple Mobile Web Clips Icon WordPress Wordpress Plugins Mobile Non Scaleable Content
Similar Organizations
Chimeron Bio
Chimeron Bio develops agents for personalized cancer gene therapy.
Current Advisors List
Founder
Investors List
Sofinnova Partners
Sofinnova Partners investment in Seed Round - AAVantgarde Bio
Official Site Inspections
http://www.aavantgardebio.com
- Host name: 104.17.17.9
- IP address: 104.17.17.9
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "AAVantgarde Bio"
AAVantgarde - Pioneers in cutting-edge AAV technology
AAVantgarde is a clinical stage, Italian-headquartered international biotechnology company with two proprietary AAV platforms for large-gene deliverySee details»
AAVantgarde Bio - Crunchbase Company Profile
Organization. AAVantgarde Bio . Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. Similar Companies. ... Contact Email [email protected]; Phone Number +39 329-552-4297; AAVantgarde …See details»
About us - AAVantgarde
Our platforms (dual hybrid and intein-mediated) are being validated in two inherited retinal diseases (IRDs) with a high unmet need: Usher syndrome type 1B (USH1B) and Stargardt disease (STGD) respectively and have the …See details»
Our team - About us - AAVantgarde
AAVantgarde Bio, based in Milan, is developing gene therapies for inherited retinal disorders. The founder, Professor Alberto Auricchio, is a highly recognized scientist and a pioneer in the field …See details»
AAVantgarde Bio - PitchBook
AAVantgarde Bio General Information Description. Developer of a gene therapy biotechnology company designed for inherited retinal disorders. The company's technology builds on proprietary Adeno-Associated Viral (AAV) vector …See details»
AAVantgarde Bio - LinkedIn
AAVantgarde is a clinical-stage, international biotechnology company (headquartered in Italy) that has developed two proprietary adeno-associated viral (AAV) vector platforms to address the DNA ...See details»
AAVantgarde Bio - Forbion
Www.aavantgardebio.com Via Vincenzo Gioberti, 8 20123 Milano Worked on by. Dmitrij Hristodorov, PhD General Partner. Dmitrij Hristodorov joined Forbion in March 2020 Read more Tim Lohoff , PhD Senior Associate. Tim is a Senior …See details»
AAVantgarde Bio - Products, Competitors, Financials, Employees ...
AAVantgarde Bio is a clinical-stage biotechnology company focused on developing proprietary adeno-associated viral (AAV) vector platforms within the biotechnology sector. Use the CB …See details»
AAVantgarde Closes €61 Million Series A Financing to …
Jun 6, 2023 AAVantgarde has two proprietary, AAV-based large gene delivery platforms: one leveraging DNA recombination, named dual hybrid; and one protein trans-splicing, named AAV intein.See details»
AAVantgarde Bio - VentureRadar
"AAVantgarde Bio is developing gene therapies for inherited retinal disorders. The founder, Professor Alberto Auricchio, is a highly recognized scientist and a pioneer in the field of gene …See details»
A large international investment in hereditary retinal …
Jun 6, 2023 The path of AAVantgarde Bio, the Tigem spin-off dedicated to the development of gene therapies for hereditary diseases of the retina, continues at full speed! The company, founded in 2021 thanks to the Sofinnova-Telethon …See details»
AAVantgarde Closes €61 Million Series A Financing to Advance …
Jun 6, 2023 - Financing led by Atlas Venture and Forbion - Company created, incubated and seed financed by Sofinnova Partners MILAN, Italy, June 06, 2023 (GLOBE NEWSWIRE) -- …See details»
TIGEM's Startup, AAVantgarde Bio, Emerges as Gene Therapy …
May 27, 2024 ©2024 TIGEM - Telethon Institute of Genetics and Medicine | Via Campi Flegrei, 34 | 80078 Pozzuoli (NA), ItalySee details»
AAVantgarde closes €61 million Series A financing to advance two ...
Jun 6, 2023 For more information, please visit: www.aavantgardebio.com. About Atlas Venture. Atlas Venture is a leading biotech venture capital firm. With the goal of doing well by doing …See details»
AAVantgarde Closes €61 Million Series A Financing to
Jun 6, 2023 For more information, please visit: www.aavantgardebio.com. About Atlas Venture Atlas Venture is a leading biotech venture capital firm. With the goal of doing well by doing …See details»
AAVantgarde appoints Ram Palanki as Chairman of its Board of …
AAVantgarde is an innovative biotechnology start-up, co-founded by Dr. Alberto Auricchio and born from the research activities carried out at Tigem (Telethon Institute of Genetics and …See details»
AAVantgarde Bio Appoints Dr. Natalia Misciattelli as Chief …
Sep 8, 2022 AAVantgarde Bio, a clinical stage Milan-based international biotechnology start-up that has developed proprietary Adeno-Associated Viral (AAV) vector platforms that allow for …See details»
AAVantgarde Bio - VentureRadar
Similar Companies: Scout Bio USA Privately Held Scout Bio is a biotechnology company focused on revolutionizing pet medicine by delivering a pipeline of one-time therapeutics for major …See details»
Longwood Fund - AAVantgarde Bio
AAVantgarde Bio is a clinical stage, Italian headquartered, international biotechnology company that has developed two proprietary Adeno-Associated Viral (AAV) vector platforms to address …See details»
Innovation - AAVantgarde
Pipeline. The company is validating its proprietary platforms in two lead programs in Ophthalmology with a high unmet need: Usher Syndrome Type 1B-associated retinitis …See details»